医学
淋巴瘤
美罗华
疾病
单克隆抗体
肿瘤科
免疫学
化疗
伯基特淋巴瘤
疟疾
内科学
抗体
作者
Elizabeth Molyneux,Rosemary Rochford,Beverly E. Griffin,Robert Newton,Graham Jackson,Menon Geetha,Christine J. Harrison,Trijn Israëls,Simon Bailey
出处
期刊:The Lancet
[Elsevier BV]
日期:2012-02-13
卷期号:379 (9822): 1234-1244
被引量:590
标识
DOI:10.1016/s0140-6736(11)61177-x
摘要
Burkitt's lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma and is the fastest growing human tumour. The disease is associated with Epstein-Barr virus and was one of the first tumours shown to have a chromosomal translocation that activates an oncogene (c-MYC). Burkitt's lymphoma is the most common childhood cancer in areas where malaria is holoendemic. The incidence is very high in immunosuppressed patients in non-endemic areas, especially when associated with HIV infection. Outcome with intensive chemotherapy has improved and is now excellent in children, but the prognosis is poor in elderly adults. The success of intensive treatment relies on good supportive care. The therapy offered in oncology units in low-income countries is not as aggressive as in centres in high-income countries and outcomes are less successful. Adjuvant monoclonal antibody therapy with rituximab shows promise for improved outcomes and reduced toxic effects in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI